Amelioration of NK cell function driven by Vα24 + invariant NKT cell activation in multiple myeloma

Iyoda, Tomonori; Yamasaki, Satoshi; Hidaka, Masaaki; Kawano, Fumio; Abe, Yu; Suzuki, Kenshi; Kadowaki, Norimitsu; Shimizu, Kazuo; Fujii, Shin‐ichiro

doi:10.1016/j.clim.2017.10.007

Cited by 20 publications

(20 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK cell cytotoxicity mostly depends on NK cell activation by IL-2 and IFN-γ production from TCR-stimulated iNKT cells [151] (Figure 1). As an anti-myeloma effect, we and others have demonstrated that NK cell cytotoxicity against primary myeloma cells depends on expression of NKG2D and DNAM-1, as well as perforin/granzyme B [99]. In fact, such characteristics of NK cells were shown in DC/Gal-treated patients [103].…”

Section: Inkt and Nk Cell-mediated Immunotherapymentioning

confidence: 88%

“…Vα24 + iNKT cells can apparently be detected in PBMCs and bone marrow mononuclear cells (BMMNCs) in patients with myeloma. However, Vα24 + iNKT cell frequency and disease progression are inversely correlated [97][98][99][100] due to at least the expression of CD1d on primary myeloma cells [98]. Premalignant and early-stage myeloma cells show high expression of CD1d, which decreases in the advanced stages [101].…”

Section: Role Of Inkt Cells Against Multiple Myeloma and Leukemiamentioning

confidence: 99%

“…iNKT cell frequency in patients with MM treated with steroid was low. However, iNKT cell populations expanded and produced IFN-γ by CD1d/Gal stimulation even in steroid-treated patients, indicating that IFN-γ-producing iNKT cells in BM are preserved in most patients with MM [99]. When patients with MM were injected with α-GalCer-pulsed dendritic cells (DCs) (DC/Gal), the iNKT cell pool expanded 100-fold and lasted for several months [102].…”

Section: Role Of Inkt Cells Against Multiple Myeloma and Leukemiamentioning

confidence: 99%

See 2 more Smart Citations

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Shimizu

Iyoda

Yamasaki

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Recent cancer treatment modalities have been intensively focused on immunotherapy. The success of chimeric antigen receptor T cell therapy for treatment of refractory B cell acute lymphoblastic leukemia has pushed forward research on hematological malignancies. Among the effector types of innate lymphocytes, natural killer (NK) cells show great importance in immune surveillance against infectious and tumor diseases. Particularly, the role of NK cells has been argued in either elimination of target tumor cells or escape of tumor cells from immune surveillance. Therefore, an NK cell activation approach has been explored. Recent findings demonstrate that invariant natural killer T (iNKT) cells capable of producing IFN-γ when optimally activated can promptly trigger NK cells. Here, we review the role of NKT and/or NK cells and their interaction in anti-tumor responses by highlighting how innate immune cells recognize tumors, exert effector functions, and amplify adaptive immune responses. In addition, we discuss these innate lymphocytes in hematological disorders, particularly multiple myeloma and acute myeloid leukemia. The immune balance at different stages of both diseases is explored in light of disease progression. Various types of innate immunity-mediated therapeutic approaches, recent advances in clinical immunotherapies, and iNKT-mediated cancer immunotherapy as next-generation immunotherapy are then discussed.

show abstract

Section: Inkt and Nk Cell-mediated Immunotherapymentioning

confidence: 88%

Section: Role Of Inkt Cells Against Multiple Myeloma and Leukemiamentioning

confidence: 99%

Section: Role Of Inkt Cells Against Multiple Myeloma and Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Shimizu

Iyoda

Yamasaki

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Such therapeutic approach increased the frequency of iNKT cells capable of producing high levels of IFN-γ, reduced metastases and showed positive clinical responses especially in MM patients [ 73 , 74 , 75 ].…”

Section: γδ T Cell Engineering Strategiesmentioning

confidence: 99%

Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells

Morandi

Yazdanifar

Cocco

et al. 2020

Cells

View full text Add to dashboard Cite

Most studies on genetic engineering technologies for cancer immunotherapy based on allogeneic donors have focused on adaptive immunity. However, the main limitation of such approaches is that they can lead to severe graft-versus-host disease (GvHD). An alternative approach would bolster innate immunity by relying on the natural tropism of some subsets of the innate immune system, such as γδ T and natural killer (NK) cells, for the tumor microenvironment and their ability to kill in a major histocompatibility complex (MHC)-independent manner. γδ T and NK cells have the unique ability to bridge innate and adaptive immunity while responding to a broad range of tumors. Considering these properties, γδ T and NK cells represent ideal sources for developing allogeneic cell therapies. Recently, significant efforts have been made to exploit the intrinsic anti-tumor capacity of these cells for treating hematologic and solid malignancies using genetic engineering approaches such as chimeric antigen receptor (CAR) and T cell receptor (TCR). Here, we review over 30 studies on these two approaches that use γδ T and NK cells in adoptive cell therapy (ACT) for treating cancer. Based on those studies, we propose several promising strategies to optimize the clinical translation of these approaches.

show abstract

“…NKT cells have long represented an attractive target for tumor immunotherapy ( 103 , 104 ). Numerous studies in both humans and mice have demonstrated their ability to directly target CD1d-expressing tumor cells ( 105 – 108 ), recruit and activate anti-tumor effector cells of the innate and adaptive immune systems ( 100 , 109 – 114 ), and control the activity of immunosuppressive cells in the tumor microenvironment. After in vivo administration of αGalCer, NKT-DC cross-talk-mediated NK cell activation results in IFN-γ response ( 82 ) and, potentially, the anti-tumor effect of αGalCer ( 85 , 115 ).…”

Section: Implications For Cancer Immunotherapymentioning

confidence: 99%

Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective

et al. 2017

View full text Add to dashboard Cite

Type I natural killer T (NKT) cells are innate-like T lymphocytes that recognize glycolipid antigens presented by the MHC class I-like protein CD1d. Agonistic activation of NKT cells leads to rapid pro-inflammatory and immune modulatory cytokine and chemokine responses. This property of NKT cells, in conjunction with their interactions with antigen-presenting cells, controls downstream innate and adaptive immune responses against cancers and infectious diseases, as well as in several inflammatory disorders. NKT cell properties are acquired during development in the thymus and by interactions with the host microbial consortium in the gut, the nature of which can be influenced by NKT cells. This latter property, together with the role of the host microbiota in cancer therapy, necessitates a new perspective. Hence, this review provides an initial approach to understanding NKT cells from an ecological evolutionary developmental biology (eco-evo-devo) perspective.

show abstract

Amelioration of NK cell function driven by Vα24 + invariant NKT cell activation in multiple myeloma

Cited by 20 publications

References 50 publications

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells

Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective

Contact Info

Product

Resources

About